Middle East And Africa Pharmaceutical Glass Packaging Market

Middle East And Africa Pharmaceutical Glass Packaging Market Analysis

The Middle East And Africa Pharmaceutical Glass Packaging Market size is worth USD 1.74 Billion in 2025, growing at an 4.39% CAGR and is forecast to hit USD 2.16 Billion by 2030.

The market quantifies the value of glass packaging products consumed in the pharmaceutical sector. This includes a range of products like bottles, vials, ampoules, cartridges, and syringes, falling within the study's market scope.

• Injectable drugs are a crucial driver for the pharmaceutical glass packaging market, propelled by the rising demand from an aging population, especially those needing medications for chronic ailments like diabetes and heart disease. The Dubai Health Authority (DHA) projects a significant shift, with the proportion of older individuals in the United Arab Emirates rising from 6% to 29% by 2050.
• The market's trajectory is shaped by multiple factors, including the escalating demand for pharmaceuticals, heightened healthcare investments, and a growing emphasis on proper medication storage. Moreover, the expanding geriatric demographic in the region is bolstering the demand for medicine glass bottles, given that older individuals typically require a higher volume of medications.
• The United Arab Emirates Ministry of Economy underscores the pharmaceutical sector's pivotal role in the Dubai Industrial Strategy 2030 and the Abu Dhabi Vision 2030. Notably, the pharmaceutical industry is poised for robust growth and exports and promises a significant medium—to long-term economic impact.
• Projections from Alpen Capital highlight a pressing need in Dubai's healthcare sector: an anticipated requirement of 8,300 more doctors and 8,800 additional nurses by 2025. The Dubai healthcare market is set to be a linchpin in propelling the broader Middle Eastern healthcare sector, forecasted to surge from USD 144 billion in 2022 to USD 243 billion by 2023.
• While aluminum and glass have traditionally dominated pharmaceutical packaging, their costs have escalated over time, making them less viable for mass consumption. This cost challenge, among other factors, paved the way for plastics to emerge as a more cost-effective packaging solution.

Middle East And Africa Pharmaceutical Glass Packaging Market Trends

Saudi Arabia is Expected to have a Significant Growth

• Saudi Arabia is one of the significant contributors to the market share in the Middle East region. The country's market witnessed various product innovations, especially pharmaceutical packaging products, owing to substantial vendors nationwide.
• The Saudi government is investing in developing the healthcare sector, which is expected to help increase the market for pharmaceutical products. The government strives to improve healthcare quality, introduce improved healthcare technology, and increase the number of hospitals and medical centers.
• The Saudi Food and Drug Administration shall be responsible for registering, evaluating, and approving medicines and medical devices in the Kingdom. Additionally, the government is launching various initiatives and programs to increase the availability of generic drugs, which is anticipated to reduce healthcare costs.
• Saudi Arabia's economic strategy for the future heavily leans on bolstering its healthcare sector. The Kingdom has made strides in enhancing its healthcare infrastructure, focusing on public-private partnerships, elevating care quality, embracing virtual healthcare platforms, and refining the supply chain. The World Health Organization projects Saudi healthcare expenditures to rise from USD 63.80 billion in 2023 to USD 69.8 billion by 2025, underscoring the region's growing healthcare infrastructure needs and the demand for diverse glass packaging products.
• Healthcare is a cornerstone of Saudi Arabia's Vision 2030, emphasizing the nation's commitment to enhancing healthcare accessibility and quality. With substantial investments, including a notable USD 66 billion injection into the private sector, Saudi Arabia is positioning itself as a leader in the Middle East's healthcare landscape. Highlighting this potential, the Organization for Economic Co-operation and Development (OECD) notes a global pharmaceutical industry growth projection of 160% over the next five years. Saudi Arabia anticipates a remarkable 232% growth from 2017 to 2030.

Vials Segment is Expected to Witness Growth

• Glass dominates the vial manufacturing landscape. Rising healthcare costs, often due to pharmaceutical mismanagement, combined with surging demands from hospitals and pharmaceutical companies are set to drive an uptick in vial usage. Glass vials' impermeability and chemical inertness make them the preferred choice for packaging both liquid and lyophilized drugs, ensuring optimal drug stability.
• Glass vials protect medicines from environmental threats such as light and moisture, extending their shelf life. Their nonporous nature ensures that the smell and taste of stored products, whether vitamins or medications, remain unaltered. This feature significantly reduces risks of evaporation and contamination, which are challenges often faced with porous container materials.
• Venus Remedies secured good manufacturing practices (GMP) certification from the Saudi Food and Drug Authority (SFDA) for seven manufacturing facilities. The SFDA's certification for Venus Remedies includes facilities for prefilled Enoxaparin syringes and general injections. Additionally, it renews approvals for Cephalosporin and Carbapenem antibiotics and liquid and lyophilized oncology drugs. Notably, Venus Remedies ranks among the world's top ten manufacturers of fixed-dosage injectables. The GMP certification spans small-volume injectables, dry powder, liquid, lyophilized, and more.
• According to the World Healthcare Organization (WHO), the health expenditures in the United Arab Emirates in 2020 were USD 19.7 billion and is expected to reach USD 26.9 billion in 2025. Driven by robust demand, the pharmaceutical sector has bolstered revenue generation in packaging, a trend poised to persist during the forecast period. In response, glass packaging manufacturers channel investments into pharmaceutical packaging to fortify their market standing.
• Packaging vendors increasingly opt for glass as a pharmaceutical material, driven by its key benefits. Glass boasts chemical durability and can withstand various chemical compositions. Furthermore, the transparency of glass vials enhances the visibility and monitoring of their contents. This transparency, combined with glass's chemical resistance to pharmaceuticals and its relative impermeability to air and moisture, offers an added layer of protection.

Middle East And Africa Pharmaceutical Glass Packaging Industry Overview

The Middle East and Africa pharmaceutical glass packaging market is consolidated. Investment in boosting production capacity by constructing a new factory will open opportunities in glass packaging. Rivalry among existing competitors is anticipated to fuel the demand for glass packaging. Some players operating in the region are Middle East Glass Manufacturing Company SAE, Arab Pharmaceutical Glass Company SAE (APG), Aradgh Group, Rak Ghani Glass LLC, and more.

Middle East And Africa Pharmaceutical Glass Packaging Market Leaders

Middle East And Africa Pharmaceutical Glass Packaging Market News

• May 2024: During the third edition of the "Make it in the Emirates Forum" in Abu Dhabi, Dubai Industrial City inked a deal with MD Pharma Factory. This forum was organized by the Ministry of Industry and Advanced Technology (MOIAT) in collaboration with the Abu Dhabi Department of Economic Development and ADNOC. With a value exceeding AED 130 million, this agreement underscores the growing allure of Dubai Industrial City for global investors and manufacturers. This business hub, championing innovation, is bolstered by the Industrial Partnership for Sustainable Economic Development.
• January 2024: Global Pharma, a pharmaceutical manufacturer in the United Arab Emirates and a wholly owned subsidiary of Dubai Investments PJSC, unveiled two new medicines. These launches, showcased at DUPHAT 2024, underscored the company's commitment to innovation and strategic collaborations. This innovative direction mirrors Globalpharma's vision: to provide diverse, effective healthcare solutions that harmonize tradition with science. Notably, the medicine is produced at Globalpharma's manufacturing facility in Dubai Investments Park (DIP).